It is very uncertain whether synbiotic changes withdrawals due to adverse events compared with placebo (very low certainty).
It is very uncertain whether synbiotic changes adverse events (any) compared with placebo (very low certainty).
It is very uncertain whether probiotic changes complete resolution of pain (at study end, as reported by study… compared with placebo (very low certainty).
It is very uncertain whether probiotic changes severity of pain (at study end, using the Faces Pain Scale) compared with placebo (very low certainty).
It is very uncertain whether probiotic changes frequency of pain (at study end, episodes per week) compared with placebo (very low certainty).
It is very uncertain whether probiotic changes withdrawals due to adverse events compared with placebo (very low certainty).
It is very uncertain whether probiotic changes adverse events (any) compared with placebo (very low certainty).
Synbiotic may leads to higher treatment success (at study end, as reported by study authors) compared with placebo (low certainty).
Synbiotic showed no clear difference in complete resolution of pain (at study end, as reported by study… compared with placebo (low certainty).
It is very uncertain whether erythromycin plus nasogastric tube lavage changes all‐cause mortality compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).
It is very uncertain whether erythromycin plus nasogastric tube lavage changes NSAEs compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).
It is very uncertain whether erythromycin plus nasogastric tube lavage changes rebleeding compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).
It is very uncertain whether erythromycin changes SAEs compared with placebo (very low certainty).
It is very uncertain whether erythromycin changes all‐cause mortality compared with placebo (very low certainty).